Cosyntropin Depot FDA Approval Status
FDA Approved: No
Brand name: Cosyntropin Depot
Company: Assertio Therapeutics, Inc.
Treatment for: Adrenocortical Insufficiency
Cosyntropin Depot is an alcohol-free, long-acting formulation of a synthetic ACTH analogue in development for use as a diagnostic in the screening of patients presumed to have adrenocortical insufficiency.
Development timeline for Cosyntropin Depot
| Date | Article |
|---|---|
| Oct 21, 2019 | Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin |
| Dec 20, 2018 | Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
